Contract analysis

I. Executive Summary The purpose of this memorandum is to analyze the letter dated September 13, 2024, transmitted by Rebecca Whitmore of Zalcourt Archer & Cole LLP on behalf of Veridian Biosciences, Inc. ("Veridian" or the "Company") in response to Penterra Pharmaceuticals Corp.'s ("Penterra" or "Buyer") Deficiency Notice dated September 6, 2024 (the "Deficiency Notice"), which was delivered pursuant to the Stock Pu

II. Background and Procedural Context A. The Deficiency Notice (September 6, 2024) On September 6, 2024, Calderwood & Harkness LLP transmitted a formal Deficiency Notice on behalf of Penterra to Veridian (with a courtesy copy to Zalcourt Archer & Cole LLP, counsel to Veridian). The Deficiency Notice, a copy of which is annexed hereto as Appendix B, identified two categories of events that, in Penterra's assessment, r

III. Detailed Analysis of Veridian's Arguments We address each of Veridian's four principal arguments below, summarizing Veridian's position and then providing our assessment of the argument's legal and factual merit. A. Argument 1: The Marlowe Asset Management-2 Clinical Data Is Preliminary and Interim

1. Veridian's Position The first and most prominent argument in the Response Letter is that the DMC interim analysis of the Marlowe Asset Management-2 Phase II trial represents, in Veridian's characterization, merely "a snapshot in time" and that the data is "inherently preliminary, immature, and subject to substantial change as the trial progresses." Veridian elaborates this argument across several pages of the Resp

2. Our Assessment The "preliminary data" argument has some surface appeal, particularly to a court unfamiliar with the specific clinical data at issue, but it is ultimately undermined by the severity and breadth of the safety signals revealed by the Marlowe Asset Management-2 interim analysis. Severity of the CRS signal. Veridian's characterization of CRS as a "known and manageable class effect" is technically accura

1. Veridian's Position Veridian's second principal argument is that its implementation of the Protocol v4.0 amendment on August 28, 2024 demonstrates proactive risk management and adequately addresses the safety concerns identified in the Marlowe Asset Management-2 interim analysis. Specifically, Veridian argues: Tocilizumab prophylaxis. Veridian asserts that the addition of mandatory tocilizumab prophylaxis to the M

2. Our Assessment The Protocol v4.0 amendment is a relevant factual development, but it does not cure the Material Adverse Effect for the reasons discussed below. In certain respects, the amendment actually strengthens Penterra's position. Dose reduction and efficacy. The most significant vulnerability in Veridian's argument is the fifty percent dose reduction from 1.5 mg/kg to 0.75 mg/kg. This reduction was presumab

1. Veridian's Position Veridian's third argument addresses the FDA partial clinical hold imposed on IND 154832 on August 22, 2024. Veridian makes the following specific assertions: Routine regulatory action. Veridian characterizes the partial clinical hold as "a routine regulatory action that is a well-understood feature of the drug development process, particularly in oncology." Veridian attaches excerpts from FDA g

2. Our Assessment Veridian's characterization of the partial clinical hold as "routine" is misleading, and its prediction of a 30-to-60-day resolution timeline is speculative and unsupported. Partial clinical holds are not routine. While partial clinical holds do occur in oncology drug development, they are not routine events. The FDA imposes clinical holds — whether partial or full — when it determines that there is

1. Veridian's Position Veridian's fourth and final argument invokes the carveouts negotiated within the MAE definition in SPA § 1.1. Veridian argues that the events cited in the Deficiency Notice fall within one or more of these carveouts and therefore cannot constitute a Material Adverse Effect under the Agreement. Specifically, Veridian advances the following three carveout arguments: Industry conditions carveout (

2. Our Assessment The carveout arguments are the least compelling aspect of Veridian's Response Letter. We address each in turn. Industry Conditions Carveout (Carveout (ii)). This is Veridian's strongest carveout argument, but it is nonetheless weak. The SPA's MAE definition carves out "conditions affecting the biotechnology or pharmaceutical industries generally." The critical word in this carveout is "generally" —

IV. Assessment of Veridian's Demand for Closing and Specific Performance Threat A. Veridian's Demand The Response Letter demands that Penterra "proceed to consummate the Closing in accordance with the terms and conditions of the Agreement without further delay." Veridian asserts that all conditions to Buyer's obligation to close under SPA §§ 7.1 (mutual conditions), 7.2 (conditions to Buyer's obligations), and 7.3 (c

V. Evaluation of Litigation Risk In light of Veridian's express threat of litigation in the Court of Chancery of the State of Delaware, we set forth below our preliminary assessment of the strengths and weaknesses of Penterra's position and our overall evaluation of litigation risk. A. Strengths of Penterra's Position Penterra's MAE position is supported by the following factors, which we expect would weigh heavily i